Advertisement

(Endogenous) Opioids and the cardiovascular system

  • James G. Bovill

Abstract

While modulation of nociception is often considered the primary effect of the endogenous opioid system, it has become clear during the past decade that this system exhibits a remarkable complexity, with functional implications for most organs, including the cardiovascular system. Endogenous Opioid peptides and their receptors are present in brain areas responsible for cardiovascular control, in the heart, in autonomic ganglia and in the adrenal medulla, and influence and regulate cardiovascular functions both centrally and peripherally. They are involved in the modulation of hypertension and in other pathological cardiovascular conditions such as congestive heart failure and myocardial ischaemia. Endogenous Opioid peptides are released upon myocardial ischaemia and contribute to the development of ischaemic arrhythmias and cardiogenic shock.1-3 Some of these effects are reversed by the opioid antagonist, naloxone.4 Dynorphin, the endogenous ligand for the k-receptors, appears to be the most potent of the endogenous opioid peptides in the induction of cardiac arrhythmias.2 The endogenous opioid peptides also appear to be involved in the pathogenesis of acute myocardial infarction.5 Both δ- and k-receptors are present in the heart,6 and large amounts of mRNA for preproenkephalin A have been identified in ventricular myocytes of rats and hamsters, suggesting that cardiac myocytes are capable of synthesising opioid peptides.7,8

Keywords

Mean Arterial Pressure Opioid Receptor Histamine Release Opioid Peptide Endogenous Opioid Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lee AY. Endogenous opioid peptides and cardiac arrhythmias. Int J Cardiol 1990; 27: 145–151.PubMedCrossRefGoogle Scholar
  2. 2.
    Wu J-P, Chen Y-T, Lee A Y-S. Opioids in myocardial ischaemia: potentiating effects of dynorphin on ischaemic arrhythmia, bradycardia and cardiogenic shock following coronary artery occlusion in the rat. Eur Heart J 1993; 14: 1273–1277.PubMedCrossRefGoogle Scholar
  3. 3.
    Imai N, Kashiki M, Woolf PD, Liang C-S. Comparison of cardiovascular effects of μ-and δ-opioid receptor antagonists in dogs with congestive heart failure. Am J Physiol 1994; 267: H912–H917.PubMedGoogle Scholar
  4. 4.
    Chen YT, Lin CJ, Lee AY, Chen JS, Hwang DS. Stereospecific blocking effects of naloxone against hemodynamic compromise and ventricular dysfunction due to myocardial ischemia and reperfusion. Int J Cardiol 1995; 50: 125–129.PubMedCrossRefGoogle Scholar
  5. 5.
    Slepushkin VD, Pavlenko VS, Zoloyev GK, et al. The role of enkephalins in the pathogenesis of acute myocardial infarction. Exp Pathol 1988; 35:129–131.PubMedCrossRefGoogle Scholar
  6. 6.
    Zimlichman R, Gefel D, Eliahou H, et al: Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation 1996; 93: 1020–1025.PubMedCrossRefGoogle Scholar
  7. 7.
    Springhorn JP, Claycomb WC. Preproenkephalin mRNA expression in developing rat heart and in cultured ventricular cardiac muscle cells. Biochem J 1989; 258: 73–78.PubMedGoogle Scholar
  8. 8.
    Ouellette M, Brakier-Gingras L. Increase in the relative abundance of preproenkephalin A messenger RNA in the ventricles of cardiomyopathic hamsters. Biochem Biophys Res Commun 1988; 155: 449–454.PubMedCrossRefGoogle Scholar
  9. 9.
    Rimoy GH, Wright DM, Bhaskar NK, Rubin PC. The cardiovascular and central nervous system effects in the human of U-62066E. A selective K-opioid receptor agonist. Eur J Clin Pharmacol 1994; 46: 203–207.PubMedCrossRefGoogle Scholar
  10. 10.
    Ventura C, Spurgeon H, Lakatta EG, Guarnieri C, Capogrossi MC. k and δ opioid receptor Stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons. Circ Res 1992; 70: 66–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Wong TM, Sheng JZ, Wong NS, Tai KK. Signal transduction in the cardiac K-receptor. Biol Signals 1995; 4: 174–178.PubMedCrossRefGoogle Scholar
  12. 12.
    Xiao R-P, Pepe S, Spurgeon HA, Capogrossi MC, Lakatta EG. Opioid peptide receptor Stimulation reverses β-adrenergic effects in rat heart cells. Am J Physiol 1997; 272: H797–H805.PubMedGoogle Scholar
  13. 13.
    Saeki T, Nishimura M, Sato N, Fujinami T, Watanabe Y. Electrophysiological demonstration and activation of μ-opioid receptors in the rabbit sinoatrial node. J Cardiovasc Pharmacol 1995; 26: 160–168.PubMedCrossRefGoogle Scholar
  14. 14.
    Fontana F, Bernardi P, Pich EM, et al. Relationship between plasma atrial natriuretic factor and Opioid peptide levels in healthy subjects and in patients with acute congestive heart failure. Eur Heart J 1993; 14: 219–225.PubMedCrossRefGoogle Scholar
  15. 15.
    Lowe H. Zur Rolle endogener Opioide bei der Herzinsuffizienz. Z Kardiol 1991; 80(Suppl 8): 47–51.PubMedGoogle Scholar
  16. 16.
    Llobel F, Laorden ML. Effects of morphine on atrial preparations obtained from nonfailing and failing human hearts. Br JAnaesth 1996; 76: 106–110.CrossRefGoogle Scholar
  17. 17.
    Van Vliet BJ, Ruuls SR, Drukarch B, Mulder AH, Schoffelmeer AN. Beta-adrenoceptor-sensitive adenylate cyclase is inhibited by activation of mu-opioid receptors in rat striatal neurons. Eur J Pharmacol 1991; 195: 295–300.PubMedCrossRefGoogle Scholar
  18. 18.
    Flacke JW, Flacke WE, Bloor BC, et al. Histamine release by four narcotics: A double-blind study in humans. Anesth Analg 1987; 66: 723–730.PubMedCrossRefGoogle Scholar
  19. 19.
    Mayer N, Zimpfer M, Raberger G, Beck A. Fentanyl inhibits the canine carotid chemoreceptor reflex. AnesthAnalg 1989; 69: 756–762.Google Scholar
  20. 20.
    Pruett JK, Blair JR, Adams RJ. Cellular and subcellular actions of Opioids in the heart. In Estafanous FG (ed): Opioids in Anesthesia, IL Boston, Butterworth-Heinemann, 1991, pp 61–71.Google Scholar
  21. 21.
    Blair JR, Pruett JK, Introna RP, et al. Cardiac electrophysiologic effects of fentanyl and sufentanil in canine cardiac Purkinje fibers. Anesthesiology 1989; 71: 565–570.PubMedCrossRefGoogle Scholar
  22. 22.
    Pugsley MK, Saint DA, Penz MP, Walker MJ. Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289. Br J Pharmacol 1993; 110: 1579–1585.PubMedCrossRefGoogle Scholar
  23. 23.
    Saini V, Carr DB, Hagestad EL, et al. Antifibrillatory action of the narcotic agonist fentanyl. Am Heart J 1988; 115: 598–605.PubMedCrossRefGoogle Scholar
  24. 24.
    Hess L, Vrana M, Vranova Z, Fejfar Z. The antifibrillatory effect of fentanyl, sufentanil and carfentanil in the acute phase of local myocardial ischaemia in the dog. Acta Cardiol 1989; 44:303–311.PubMedGoogle Scholar
  25. 25.
    Goldberg AH, Padget CH. Comparative effects of morphine and fentanyl on isolated heart muscle. AnesthAnalg 1969; 48: 978–982.Google Scholar
  26. 26.
    Strauer B. Contractile responses to morphine, piritramide, meperidine and fentanyl: A comparative study of effects on the isolated ventricular myocardium. Anesthesiology 1972; 37:304–310.PubMedCrossRefGoogle Scholar
  27. 27.
    Sullivan DL, Wong KC. The effects of morphine on the isolated heart during normothermia and hypothermia. Anesthesiology 1973; 38: 550–556.PubMedCrossRefGoogle Scholar
  28. 28.
    Chen Zhang C, Su JY, Calkins D. Effects of alfentanil on isolated cardiac tissues of the rabbit. Anesth Analg 1990; 71: 268–274.CrossRefGoogle Scholar
  29. 29.
    Kohno K, Takaki M, Ishioka K, et al. Effects of intracoronary fentanyl on left ventricular mechanoenergetics in the excised cross-circulated canine heart. Anesthesiology 1997; 86: 1350–1358.PubMedCrossRefGoogle Scholar
  30. 30.
    Lowenstein E, Whiting RB, Bittar DA, Sanders CA, Powell WJ Jr. Local and neurally mediated effects of morphine on skeletal muscle vascular resistance. J Pharmacol Exp Ther 1972; 180: 359–367.PubMedGoogle Scholar
  31. 31.
    White DA, Reitan JA, Kien ND, Thorup SJ. Decrease in vascular resistance in the isolated canine hindlimb after graded doses of alfentanil, fentanyl, and sufentanil. AnesthAnalg 1990; 71:29–34.Google Scholar
  32. 32.
    Karasawa F, Iwanov V, Moulds RF. Effects of fentanyl on the rat aorta are mediated by alpha-adrenoceptors rather than by the endothelium. Br J Anaesth 1993; 71: 877–880.PubMedCrossRefGoogle Scholar
  33. 33.
    Nagamachi K, Shitara K, Yamashita Y, et al. H Role of endogenous Opioids and central Opioid receptors in cerebral cortical blood flow autoregulation. Jpn J Physiol 1995; 45: 137–149.PubMedCrossRefGoogle Scholar
  34. 34.
    Benyo Z, Wahl M. Opiate receptor-mediated mechanisms in the regulation of cerebral blood flow. Cerebrovasc Brain Metab Rev 1996; 8: 326–357.PubMedGoogle Scholar
  35. 35.
    Armstead WM. Role of Opioids in the physiologic and pathophysiologic control of the cerebral circulation. Proc Soc Exp Biol Med 1997; 214: 210–221.PubMedGoogle Scholar
  36. 36.
    Schregel W, Weyerer W, Cunitz G. Opioide, Hirndurchblutung und intrakranieller Druck. Anaesthesist 1994; 43: 421–430.PubMedCrossRefGoogle Scholar
  37. 37.
    Holaday JW, Faden AI. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature 1978; 275: 450–451.PubMedCrossRefGoogle Scholar
  38. 38.
    Faden AI, Holaday JW. Naloxone treatment of endotoxin shock: stereospecificity of physiologic and pharmacologic effects in the rat. J Pharmacol Exp Ther 1980; 212:441–447.PubMedGoogle Scholar
  39. 39.
    Safani M, Blair J, Ross D, Waki R, Li C, Libby G. Prospective, controlled, randomized trial of naloxone infusion in early hyperdynamic septic shock. Crit Care Med 1989; 17: 1004–1009.PubMedCrossRefGoogle Scholar
  40. 40.
    Hackshaw KV, Parker GA, Roberts JW. Naloxone in septic shock. Crit Care Med 1990; 18: 47–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Sagy M, Shavit G, Oron Y, Vidne BA, Gitter S, Sarne Y. Nonopiate effect of naloxone on cardiac muscle contractility. J Cardiovasc Pharmacol 1987; 9: 682–685.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • James G. Bovill

There are no affiliations available

Personalised recommendations